Vivosim Labs, Inc. (VIVS) — SEC Filings
Vivosim Labs, Inc. (VIVS) — 42 SEC filings. Latest: 424B4 (Apr 2, 2026). Includes 21 8-K, 6 10-Q, 2 S-1/A.
View Vivosim Labs, Inc. on SEC EDGAR
Overview
Vivosim Labs, Inc. (VIVS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 1, 2026: VivoSim Labs, INC. filed an EFFECT form on April 1, 2026, indicating the effectiveness of a registration statement. The filing, with SEC Accession No. 9999999995-26-001032, was accepted on April 1, 2026, with an effectiveness date of March 31, 2026. The company is located at 11555 Sorrento Valley Ro
Sentiment Summary
Across 42 filings, the sentiment breakdown is: 7 bearish, 34 neutral, 1 mixed. The dominant filing sentiment for Vivosim Labs, Inc. is neutral.
Filing Type Overview
Vivosim Labs, Inc. (VIVS) has filed 1 424B4, 1 EFFECT, 2 S-1/A, 21 8-K, 6 10-Q, 2 DEF 14A, 2 10-K/A, 2 10-K, 1 SC 13G, 2 S-1, 2 SC 13G/A with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (42)
Risk Profile
Risk Assessment: Of VIVS's 38 recent filings, 7 were flagged as high-risk, 13 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $65,000 |
| Net Income | -$5,388,000 |
| EPS | N/A |
| Debt-to-Equity | 0.37 |
| Cash Position | $6,677,000 |
| Operating Margin | -8550.8% |
| Total Assets | $9,686,000 |
| Total Debt | $2,621,000 |
Key Executives
- Keith Murphy
- Jeffrey T. Hartlin
- Samantha H. Eldredge
- M. Ali Panjwani, Esq.
- Douglas Jay Cohen
- David Gobel
- David Harris
Industry Context
VivoSim Labs operates in the biotechnology or medical device sector, likely focusing on simulation technologies for healthcare applications. This industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Competition can be intense, with established players and numerous startups vying for market share and funding.
Top Tags
Biotechnology (6) · regulatory-filing (6) · financials (6) · sec-filing (5) · SEC Filing (5) · corporate-governance (5) · 8-K (4) · 8-k (4) · 10-Q (4) · filing (3)
Executive Compensation
From the most recent DEF 14A filing (Nov 3, 2025):
- Douglas Jay Cohen — Director
- David Gobel — Director
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Acceptance Date | 2026-04-01 | Date the filing was accepted by the SEC. |
| Effectiveness Date | 2026-03-31 | Date the registration statement became effective. |
| Maximum aggregate offering amount | $4,000,000 | Targeted capital raise, subject to 'best efforts' basis |
| Maximum shares of common stock or pre-funded warrants | 2,366,862 | Number of primary securities offered |
| Common Warrants to Purchase Shares | 3,550,293 | Number of common warrants offered, 1.5 per share/pre-funded warrant |
| Placement Agent Warrants | 118,343 | Warrants issuable to Joseph Gunnar & Co., LLC |
| Assumed combined public offering price per share | $1.69 | Based on VIVS closing price on March 26, 2026 |
| Initial exercise price of common warrants | $2.03 | 120% of the assumed combined public offering price |
| Exercise price of Placement Agent Warrants | $2.11 | 125% of the assumed combined public offering price |
| Placement Agent cash fee | 7.5% | Percentage of aggregate purchase price paid to Joseph Gunnar & Co., LLC |
| Common warrant price protection floor | $0.01 | Minimum exercise price for common warrants |
| Shares registered for common warrant exercise | 250% | Percentage of initially issuable shares registered, indicating significant potential dilution |
| SEC File Number | 001-35996 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 271488943 | Company's tax identification number. |
| Net Loss (Q3 2025) | $2.545M | Slightly improved from $2.549M in Q3 2024, but still a significant loss. |
Forward-Looking Statements
- {"claim":"Organovo will need to raise additional capital within the next 12-18 months to continue funding its operations and R&D.","entity":"ORGANOVO HOLDINGS, INC.","targetDate":"2025-06-30","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Vivosim Labs, Inc. (VIVS)?
Vivosim Labs, Inc. has 42 recent SEC filings from Feb 2024 to Apr 2026, including 21 8-K, 6 10-Q, 2 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of VIVS filings?
Across 42 filings, the sentiment breakdown is: 7 bearish, 34 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Vivosim Labs, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Vivosim Labs, Inc. (VIVS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Vivosim Labs, Inc.?
Key financial highlights from Vivosim Labs, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for VIVS?
The investment thesis for VIVS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Vivosim Labs, Inc.?
Key executives identified across Vivosim Labs, Inc.'s filings include Keith Murphy, Jeffrey T. Hartlin, Samantha H. Eldredge, M. Ali Panjwani, Esq., Douglas Jay Cohen and 2 others.
What are the main risk factors for Vivosim Labs, Inc. stock?
Of VIVS's 38 assessed filings, 7 were flagged high-risk, 13 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Vivosim Labs, Inc.?
Recent forward-looking statements from Vivosim Labs, Inc. include guidance on {"claim":"Organovo will need to raise additional capital within the next 12-18 months to continue funding its operations.